Has Mouhanned Eliliwi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,071 in general payments to Mouhanned Eliliwi, MD across 24 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mouhanned Eliliwi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mouhanned Eliliwi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mouhanned Eliliwi, MD

Pulmonary Disease · Phoenix, AZNPI 1417453895

Payments from drug & device makers

$5,071in general payments, 2019–2025

Across 24 payments — averaging $211.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intuitive Surgical$3K
AstraZeneca$693
Lilly USA, LLC$249
Bayer$224
Pulmonx Corporation$176
AbbVie$125
plus $165 from 4 others

What the payments were for

Travel & lodging$61112%
Food & beverage$1,83537%
Education$2,50051%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intuitive Surgical	7	$3,439
AstraZeneca	6	$693
Lilly USA, LLC	2	$249
Bayer	2	$224
Pulmonx Corporation	1	$176
AbbVie	1	$125
Pinnacle Biologics, Inc	1	$76
Getinge USA Sales, LLC	2	$55
Edwards Lifesciences	1	$22
Pfizer	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,071 in reported general payments places this provider in the 60th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona →

Medicare billing

Part B allowed, 2024

$20,878

Medicare patients

Services billed

151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Spiriva HandihalerTiotropium Bromide	23	$11,942
Incruse ElliptaUmeclidinium Bromide	15	$8,278
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	15	$5,663
Stiolto RespimatTiotropium Br/Olodaterol Hcl	11	$5,016
Albuterol Sulfate HfaAlbuterol Sulfate	25	$670

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Phoenix

David BaratzPhoenix$2.2M
James RossPhoenix$2M
Rajat WaliaPhoenix$1.9M
Mark GotfriedPhoenix$1.1M
Abid KhokarPhoenix$321K
Brian PorvinPhoenix$276K
Tony HodgesPhoenix$262K
Rajeev SaggarPhoenix$219K
Ali SaeedPhoenix$213K
Bhuvin BuddhdevPhoenix$202K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →